Lenacapavir in first-line therapy

Lancet HIV. 2023 Jan;10(1):e2-e3. doi: 10.1016/S2352-3018(22)00375-7.

Author

Affiliation

¹ Blizard Institute, The Faculty of Medicine and Dentistry, Queen Mary University of London, The Blizard Building, 4 Newark Street, London E1 2AT, UK. Electronic address: c.m.orkin@qmul.ac.uk.

PMID: 36566080
DOI: 10.1016/S2352-3018(22)00375-7

No abstract available

Publication types

Comment

MeSH terms

Drug Therapy, Combination
HIV Infections* / drug therapy
Humans
Treatment Outcome